Evidence map›Paper›PMID 24941463›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2014

Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model.

Yuan Tang, Xiaoliang Gan, Rabe'e Cheheltani, Elizabeth Curran, Giuseppina Lamberti, Barbara Krynska, Mohammad F Kiani, Bin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Fibrin-Enriched Cardiac Extracellular Matrix Hydrogel PromotesACS biomaterials science & engineering · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Functions of Mesenchymal Stem Cells in Cardiac Repair.Advances in experimental medicine and biology · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. 1,25(OH)Drug design, development and therapy · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yuan TangDepartment of Biomedical Engineering, Widener University, Chester, PA USA; Department of Mechanical Engineering, Temple University, Philadelphia, PA USA.
Xiaoliang GanDepartment of Anesthesiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong China.
Rabe'e CheheltaniDepartment of Mechanical Engineering, Temple University, Philadelphia, PA USA.
Elizabeth CurranDepartment of Mechanical Engineering, Temple University, Philadelphia, PA USA.
Giuseppina LambertiDepartment of Mechanical Engineering, Temple University, Philadelphia, PA USA.
Barbara KrynskaShriners Hospitals Pediatric Research Center and Department of Neurology, Temple University School of Medicine, Philadelphia, PA USA.
Mohammad F KianiDepartment of Mechanical Engineering, Temple University, Philadelphia, PA USA.
Bin WangDepartment of Biomedical Engineering, Widener University, Chester, PA USA; Department of Mechanical Engineering, Temple University, Philadelphia, PA USA. Electronic address: bwang@wumail.widener.edu.
Temple University · USThird Affiliated Hospital of Sun Yat-sen University · CN

Funding

A novel microfluidic device for the study of leukocyte adhesion and migrationR21HL109794 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KIANI, MOHAMMAD F · 2011 to 2012
$421k
NHLBI NIH HHS R21 HL109794
6 · The paper itself

Abstract

Rebuilding of infarcted myocardium by mesenchymal stem cells (MSCs) has not been successful because of poor cell survival due in part to insufficient blood supply after myocardial infarction (MI). We hypothesize that targeted delivery of vascular endothelial growth factor (VEGF) to MI can help regenerate vasculature in support of MSC therapy in a rat model of MI. VEGF-encapsulated immunoliposomes targeting overexpressed P-selectin in MI tissue were infused by tail vein immediately after MI. One week later, MSCs were injected intramyocardially. The cardiac function loss was moderated slightly by targeted delivery of VEGF or MSC treatment. Targeted VEGF+MSC combination treatment showed highest attenuation in cardiac function loss. The combination treatment also increased blood vessel density (80%) and decreased collagen content in post-MI tissue (33%). Engraftment of MSCs in the combination treatment group was significantly increased and the engrafted cells contributed to the restoration of blood vessels. FROM THE CLINICAL EDITOR: VEGF immunoliposomes targeting myocardial infarction tissue resulted in significantly higher attenuation of cardiac function loss when used in combination with mesenchymal stem cells. MSCs were previously found to have poor ability to restore cardiac tissue, likely as a result of poor blood supply in the affected areas. This new method counterbalances that weakness by the known effects of VEGF, as demonstrated in a rat model.

Indexed as

AnimalsBlood VesselsCollagenDisease Models, AnimalMesenchymal Stem Cell TransplantationMyocardial InfarctionRatsVascular Endothelial Growth Factor ACollagenVascular Endothelial Growth Factor AAngiogenesisLiposomeMesenchymal stem cellsMyocardial infarctionMyocardial infarction animal model

Identifiers

PMID24941463
PMCPMC4253977
OpenAlexW1971727948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.